fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Researchers examine role of hormone in response to ovarian cancer treatment

PUBLIC RELEASE DATE: 17-Sep-2014The work comes out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, of Women & Infants' Program in Women's Oncology. Entitled "HE4 expression is associated with hormonal elements and mediated by ... [Published EurekAlert! - 4 hours ago]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Court Report - September 2014 #4

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd. et al.1:14-cv-01156; filed September 10, 2014 in the District Court of Delaware• Plaintiff:  ... [Published JD Supra - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Array BioPharma : Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published 4 Traders - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

CDK 4/6, PI3K Inhibitor Combinations Explored in Breast Cancer

Pamela N. Munster, MDThe combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer, according phase Ib data presentation by ... [Published OncLive - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Groundbreaking drug trial offers new hope to Welsh breast cancer patients

A radiographer has become the first person in the world to trial a new drug combination which doctors hope could help women with breast cancer.Susanne Jones, from Barry in the was diagnosed with breast cancer in 2006.A year-and-a-half after treatment, ... [Published Wales Online - Sep 10 2014]
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

Mahmoud Charif, MDThe addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with estrongen receptor (ER)-positive metastatic breast cancer, according a presentation by Mahmoud Charif, MD, at the ... [Published OncLive - Sep 07 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pfizer : Announces Submission of Palbociclib New Drug Application to the FDA

By a News Reporter-Staff News Editor at Biotech Week -- Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, ... [Published 4 Traders - Aug 28 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Palbociclib Submitted to FDA for Breast Cancer Approval

the Cancer Therapy Advisor take:Pfizer has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for palbociclib for the treatment of estrogen receptor-positive and human epidermal growth factor 2-negative advanced breast cancer ... [Published Chemotherapy Advisor - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 1 reports

Pfizer Submits Palbociclib Marketing Application to the FDA

Pfizer Inc. ( PFE - Analyst Report ) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA. The company is looking to get the candidate approved in combination with Novartis’ ( NVS - Analyst ... [Published Zacks.com - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Pfizer Announces Submission of Palbociclib New Drug Application To The FDA

Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the ... [Published Benzinga.com - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Modeling Luminal breast cancer heterogeneity: combination therapy to suppress a hormone ...

IntroductionMany Luminal breast cancers are heterogeneous, containing substantial numbers of estrogen (ER) and progesterone (PR) receptor-negative cells among the ER?+?PR?+?ones. One such subpopulation we call ?Luminobasal? is ER-, PR- and cytokeratin ... [Published 7thSpace - Aug 13 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 12, Authorised

Quotes

"We are not certain but believe this might mean there could be a subset of women whose tumors are more likely to respond to hormonal therapy. Moreover, we might be able to eventually identify which tumors these are and target treatment" Moore says
Infringement of U S Patent Nos. 8,017,615 ( "Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof" issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), and 8,642,760 (same title, issued February 4, 2014) following a Paragraph...
"I am pleased to join the Array team at such an exciting time in the company's evolution," said Dr. Sandor. "In addition to the impressive portfolio of clinical-stage assets in development by Array's partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need."
"Today's submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer" said Garry Nicholson , President, Pfizer Oncology...

More Content

All (18) | News (17) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Researchers examine role of hormone in response... [Published EurekAlert! - 4 hours ago]
Court Report - September 2014 #4 [Published JD Supra - Sep 15 2014]
Array BioPharma : Appoints Victor Sandor, M.D.,... [Published 4 Traders - Sep 11 2014]
CDK 4/6, PI3K Inhibitor Combinations Explored i... [Published OncLive - Sep 11 2014]
Groundbreaking drug trial offers new hope to We... [Published Wales Online - Sep 10 2014]
Adding Trastuzumab to Fulvestrant Prolongs Resp... [Published OncLive - Sep 07 2014]
Pfizer : Announces Submission of Palbociclib Ne... [Published 4 Traders - Aug 28 2014]
Palbociclib Submitted to FDA for Breast Cancer ... [Published Chemotherapy Advisor - Aug 21 2014]
Pfizer Submits Palbociclib Marketing Applicatio... [Published Zacks.com - Aug 19 2014]
Pfizer Announces Submission of Palbociclib New ... [Published Benzinga.com - Aug 18 2014]
Pfizer Announces Submission of Palbociclib New ... [Published Wall Street Select - Aug 18 2014]
Modeling Luminal breast cancer heterogeneity: c... [Published 7thSpace - Aug 13 2014]
Mount Kisco Medical Group and Northern Westches... [Published PRWeb - Jun 24 2014]
Pfizer to submit palbociclib NDA with US FDA ba... [Published PharmaBiz - May 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.